Asterand plc (ATD.L) said it has extended its collaboration with Bristol-Myers Squibb Co. (BMY) for access to Asterand's products and services for up to 3 years. The company noted that the agreement will focus on access to Asterand's PhaseZERO drug discovery services and Asterand's XpressBANKTM of human tissue and clinical samples for the continued validation of early drug targets and support for compound optimisation.
Under the extended collaboration, Asterand said it will continue to undertake a range of PhaseZERO studies for Bristol-Myers Squibb in the areas of compound profiling and target validation. PhaseZERO studies include gene and protein expression profiling and cell-based pharmacology assays.
Likewise, the company also stated that Bristol-Myers Squibb will be granted access to its XpressBANKTM of human tissue, bio-fluid, and cell lines and may also utilize Asterand's ProCURETM custom clinical sample collection service.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.